Sarah B. Kavanagh serves as Executive at Valeant Pharmaceuticals International, Inc., where they oversee executive responsibilities. Since joining the company, Sarah B. Kavanagh has executed 14 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Aug 2, 2024 involved receiving (via award) 14,696 shares valued at $0.
Sarah B. Kavanagh currently holds 33,361 shares of Valeant Pharmaceuticals International, Inc. (VRX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sarah B. Kavanagh has been a net neutral trader of VRX stock. They have purchased $0 and sold $0 worth of shares.
Sarah B. Kavanagh's most recent insider trade was on Aug 2, 2024, when they sold 14,696 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| May 19, 2023 | BHC | $0 | Award | 29,205 | $N/A | Discretionary |
| May 4, 2023 | BLCO | $0 | Award | 12,857 | $N/A | Discretionary |
| Apr 24, 2023 | BLCO | $114.6K | Payment | 6,692 | $17.12 | Discretionary |
| Jun 24, 2022 | BHC | $0 | Award | 34,387 | $N/A | Discretionary |
| May 10, 2022 | BLCO | $0 | Award | 12,500 | $N/A | Discretionary |
| Apr 30, 2021 | BHC | $0 | Award | 7,645 | $N/A | Discretionary |
| May 1, 2020 | BHC | $0 | Award | 11,037 | $N/A | Discretionary |
| May 3, 2019 | BHC | $250.0K | Award | 10,633 | $23.51 | Discretionary |
| May 3, 2018 | VRX | $0 | Award | 14,285 | $N/A | Discretionary |
| May 3, 2018 | VRX | $0 | Award | 13,881 | $N/A | Discretionary |
| May 5, 2017 | VRX | $0 | Award | 25,406 | $N/A | Discretionary |
| Jul 27, 2016 | VRX | $0 | Award | 14,458 | $N/A | Discretionary |